We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ocular Surface Changes in Patients With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00345280
Recruitment Status : Unknown
Verified June 2008 by University of Bialystok.
Recruitment status was:  Recruiting
First Posted : June 28, 2006
Last Update Posted : June 17, 2008
Sponsor:
Information provided by:

June 27, 2006
June 28, 2006
June 17, 2008
August 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00345280 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Ocular Surface Changes in Patients With Cystic Fibrosis
Chosen Parameters of the Immune Response in the Origin of Ocular Changes in Patients With Cystic Fibrosis
Cystic fibrosis(CF) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.It is caused by mutations in the protein-coding gene which function as the cystic fibrosis transmembrane regulator (CFTR), responsible for the secretion of chloride ions in epithelial cells, adenocytes, sweat gland cells, pancreatic ducts,alimentary and respiratory tracts and eye. Assessment of the relationship between the inflammatory processes and apoptosis in the eye in the course of cystic fibrosis will allow determination of immunological exponents which may facilitate diagnosis.
The aim: To assess the role of chosen parameters of immunological response in the induction of ocular changes in cystic fibrosis patients, particularly chosen chemokine concentrations in the tear fluid and analysis of chosen apoptotic markers expression on conjunctival epithelial cells.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
26 male and female patients aged 3-25 with clinically definite diagnosis of cystic fibrosis
Eye Manifestations
Procedure: impression cytology, obtain the tear fluid
Vitamin A
Other Name: Becton Dickinson
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
26
September 2008
Not Provided

Inclusion Criteria:

  • male and female patients aged 3-25 with clinically definite diagnosis of cystic fibrosis
  • all patients must give written consent for participation in the study at screening

Exclusion Criteria:

  • patients with a history of chronic disease of the immune system
  • patients with the history of systemic diseases
  • patients with the history chronic ocular diseases
  • patients who have been treated with corticosteroids in the past 3 months prior to the screening visit
Sexes Eligible for Study: All
3 Years to 25 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Poland
 
 
NCT00345280
8789
N40605131/1894
No
Not Provided
Not Provided
Malgorzata Mrugacz, Medical University of Bialystok, Poland
University of Bialystok
Not Provided
Principal Investigator: Malgorzata Mrugacz, MD, PhD Department of Pediatric Ophthalmology Medical University of Bialystok, Poland
University of Bialystok
June 2008